Literature DB >> 12909569

Future studies of low-activity PON1 phenotype subjects may reveal how PON1 protects against cardiovascular disease.

Bert N La Du.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12909569     DOI： 10.1161/01.ATV.0000082600.42562.7F

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN： 1079-5642            Impact factor:   8.311


× No keyword cloud information.
  7 in total

Review 1.  Pharmacogenetics of paraoxonase activity: elucidating the role of high-density lipoprotein in disease.

Authors:  Daniel Seung Kim; Judit Marsillach; Clement E Furlong; Gail P Jarvik
Journal:  Pharmacogenomics       Date:  2013-09       Impact factor: 2.533

Review 2.  Human PON1, a biomarker of risk of disease and exposure.

Authors:  C E Furlong; S M Suzuki; R C Stevens; J Marsillach; R J Richter; G P Jarvik; H Checkoway; A Samii; L G Costa; A Griffith; J W Roberts; D Yearout; C P Zabetian
Journal:  Chem Biol Interact       Date:  2010-03-23       Impact factor: 5.192

Review 3.  Paraoxonase 1 status as a risk factor for disease or exposure.

Authors:  Rebecca J Richter; Gail P Jarvik; Clement E Furlong
Journal:  Adv Exp Med Biol       Date:  2010       Impact factor: 2.622

4.  Paraoxonase 1 (PON1) status and substrate hydrolysis.

Authors:  Rebecca J Richter; Gail P Jarvik; Clement E Furlong
Journal:  Toxicol Appl Pharmacol       Date:  2008-11-13       Impact factor: 4.219

Review 5.  Pharmacogenetics of paraoxonases: a brief review.

Authors:  D I Draganov; B N La Du
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-10-25       Impact factor: 3.000

6.  Effects of intronic and exonic polymorphisms of paraoxonase 1 (PON1) gene on serum PON1 activity in a Korean population.

Authors:  Sang-Yong Eom; Yun-Sik Kim; Chung-Jong Lee; Chul-Ho Lee; Yong-Dae Kim; Heon Kim
Journal:  J Korean Med Sci       Date:  2011-05-18       Impact factor: 2.153

7.  PON1 status evaluation in patients with chronic arterial occlusion of lower limbs due to atherosclerosis obliterans.

Authors:  Magdalena P Kasprzak; Maria Iskra; Wacław Majewski; Magdalena Budzyń-Napierała; Bogna Gryszczyńska; Krzysztof Strzyżewski; Jakub Kasprzak
Journal:  Arch Med Sci       Date:  2014-12-22       Impact factor: 3.318
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.